Pain Management

Arthriten may offer relief from minor arthritis pain.

It is the role of the pharmacist to ensure patients are adequately counseled on the adverse effects and potential harms of codeine.

Buprenorphine (Butrans) is a partial opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.

Lyrica is indicated for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, spinal cord injury nerve pain, and pain after shingles in adult patients.

It is vital to have a robust controlled substance monitoring program to promptly identify and mitigate drug diversion.

OTC Sciatica Therapy helps relieve sciatica pain, including difficulty moving, burning, and tingling in the legs, toes, and feet.

Analysis also shows a reduction in the need for opiate painkillers, and there was a decrease in other cancer-related symptoms, according to results published in Frontiers in Pain Research.

Hospital pharmacists can play an instrumental role in controlling the misuse of opioids while ensuring appropriate pain management for their patients.

In patients already using analgesics for pain control, pharmacists need to address medication adherence for improved osteoarthritis symptom control.

Chicago Tylenol murders still reverberates after 40 years; they changed medication packaging forever.

OTC leg cramp medications may help with pain caused by cramping in the calf and foot.

Expediting the dispensing process makes sense, but take care when entering and verifying script.

BC MAX Strength Fast Pain Relief Powders work fast to relieve tough headaches, body aches, aches and pains, and menstrual cramps.

DenTek Instant Pain Relief helps soothe pain from toothaches, sore gums, and mouth sores.

Extra Strength Back & Body pain reliever treats minor body aches.

Ron Lanton, JD, principal at Lanton Law, discussed the recent Johnson & Johnson legal settlement in Texas to resolve opioid claims.

Although the ISMP created the guidelines for hospitals, they are applicable in other health care settings.

When states legalize marijuana, the volume of prescriptions within the drug classes that align with the medical indications for pain, depression, anxiety, sleep, psychosis, and seizures significantly decline.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discussed how investigative psychedelic-assisted therapy could help address both opioid addiction and chronic pain management.

Rita Roy, MD, CEO of the National Spine Health Foundation, discusses some alternative treatment plans for chronic back pain to help address the opioid epidemic.

Lidocaine is a local anesthetic that offers temporary relief of pain and itching.

BioFreeze is a cold therapy for sore muscles, backaches, and joint pain.

Jeffrey B. Simon, JD, co-chair of the National Opioid Litigation Conference, discusses some steps that pharmacists could take to help address the opioid epidemic in the pharmacy.

Daniel Krinsky, MS, owner and president of EduCare4U and PGx101, and Stefanie Ferreri, PharmD, Smith and Olsen Distinguished professor at the Eshelman School of Pharmacy in the University of North Carolina, discuss the additions, removals, and changed to OTC products in the past 2 years.

Opening the door for communication in a nonjudgmental manner is essential for pharmacists to counsel patients on cannabis use.

Session at the American Pharmacists Association Annual Meeting discusses the importance of naloxone in reducing the burden of the opioid epidemic.

Jeffrey B. Simon, JD, co-chair of the National Opioid Litigation Conference, discusses what the National Opioid Litigation Conference is and what its involvement is in opioid lawsuits across the country.

Michael Abrams, MPH, PhD, senior health researcher at Public Citizen’s Health Research Group, discusses actions needed to help manage the opioid epidemic in the country.

Jeffrey B. Simon, JD, co-chair of the National Opioid Litigation Conference, discusses the historic settlement in a multi-district opioid lawsuit in Texas.

Michael Abrams, MPH, PhD, senior health researcher at Public Citizen’s Health Research Group, discusses whether classification of gabapentin as schedule V would end patients’ access to the drug.